MONTI, SARA
 Distribuzione geografica
Continente #
NA - Nord America 1.980
AS - Asia 1.355
EU - Europa 994
SA - Sud America 185
AF - Africa 70
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.587
Nazione #
US - Stati Uniti d'America 1.927
CN - Cina 462
SG - Singapore 409
IE - Irlanda 317
HK - Hong Kong 178
RU - Federazione Russa 151
BR - Brasile 146
DE - Germania 139
VN - Vietnam 120
IT - Italia 85
FI - Finlandia 75
FR - Francia 53
GB - Regno Unito 40
ZA - Sudafrica 39
IN - India 35
BD - Bangladesh 26
SE - Svezia 26
CA - Canada 25
AT - Austria 21
ES - Italia 21
MX - Messico 18
AR - Argentina 16
ID - Indonesia 13
IQ - Iraq 13
PK - Pakistan 13
TR - Turchia 12
NL - Olanda 11
JP - Giappone 10
PL - Polonia 10
SA - Arabia Saudita 10
BE - Belgio 9
EC - Ecuador 8
LT - Lituania 8
SN - Senegal 8
CZ - Repubblica Ceca 7
EG - Egitto 7
UA - Ucraina 7
JO - Giordania 6
MY - Malesia 6
CO - Colombia 5
UZ - Uzbekistan 5
NP - Nepal 4
PH - Filippine 4
AE - Emirati Arabi Uniti 3
BH - Bahrain 3
DK - Danimarca 3
ET - Etiopia 3
KE - Kenya 3
KZ - Kazakistan 3
LK - Sri Lanka 3
PE - Perù 3
PY - Paraguay 3
AM - Armenia 2
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GD - Grenada 2
LB - Libano 2
LY - Libia 2
MA - Marocco 2
OM - Oman 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
BY - Bielorussia 1
CH - Svizzera 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
IR - Iran 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
KR - Corea 1
LV - Lettonia 1
MM - Myanmar 1
MT - Malta 1
MV - Maldive 1
NO - Norvegia 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SO - Somalia 1
SV - El Salvador 1
TG - Togo 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
YT - Mayotte 1
Totale 4.587
Città #
Dublin 313
Chandler 309
Singapore 234
San Jose 223
Ashburn 191
Dallas 178
Hong Kong 175
Beijing 126
New York 64
Los Angeles 60
Boardman 57
Helsinki 56
Munich 53
Princeton 51
Lauterbourg 49
Lawrence 46
Ho Chi Minh City 45
Shanghai 42
Nanjing 34
Johannesburg 33
Hanoi 30
Jacksonville 28
Medford 28
Wilmington 28
Council Bluffs 26
Chicago 25
Moscow 25
Buffalo 19
Redondo Beach 19
Changsha 18
Nanchang 18
Vienna 18
Pavia 17
Seattle 15
São Paulo 15
Frankfurt am Main 14
Orem 14
Santa Clara 13
Brooklyn 12
Falkenstein 12
Fairfield 11
Hangzhou 11
Hebei 11
Milan 11
Turku 10
Brussels 9
Jiaxing 9
London 9
Montreal 9
Toronto 9
Warsaw 9
Washington 9
Chennai 8
Da Nang 8
Dakar 8
Manchester 8
Phoenix 8
Shenyang 8
Tokyo 8
Ankara 7
San Francisco 7
Amman 6
Amsterdam 6
Atlanta 6
Columbus 6
Denver 6
Tianjin 6
Belo Horizonte 5
Boston 5
Brno 5
Cagliari 5
Jakarta 5
Norwalk 5
Nuremberg 5
Rio de Janeiro 5
Tashkent 5
The Dalles 5
Albuquerque 4
Berlin 4
Guangzhou 4
Houston 4
Jeddah 4
Mexico City 4
Poplar 4
Redwood City 4
Stockholm 4
Ann Arbor 3
Anápolis 3
Cape Town 3
Colombo 3
Genoa 3
Karachi 3
Kuala Lumpur 3
Manama 3
Miami 3
Mumbai 3
Pune 3
Querétaro 3
Quito 3
Riyadh 3
Totale 3.084
Nome #
Is it really infective endocarditis? Distinguishing systemic vasculitis from its mimics 132
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 128
20 years of experience with tumour necrosis factor inhibitors: what have we learned? 126
Cytomegalovirus colitis unmasking human immunodeficiency virus infection as a cause of IgA vasculitis 120
The role of Trimethoprim/sulfametoxazole in reducing relapses and risk of infec-tions in ANCA-associated vasculitis: a meta-analysis 119
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 113
Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management 112
Impact of immunosuppressive treatment on the immunogenicity of mRNA Covid-19 vaccine in vulnerable patients with giant cell arteritis 110
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 109
Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse 108
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 104
Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis 104
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 99
The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature 98
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 97
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies 97
Novel Therapies for ANCA-associated Vasculitis 96
Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis 96
Lumbar spondylolisthesis associated with systemic sclerosis-related spinal calcinosis: an unusual clinical case 95
Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis 94
Chronic pain: The burden of disease and treatment innovations 93
Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs 92
Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature 90
Novel Diagnostic and Prognostic Approaches to Systemic Vasculitides 89
Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners 89
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors 87
Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the Patient Global Assessment 86
Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis 85
Clinical spectrum of anti-Jo-1-associated disease 83
Retention rate of IL-1 inhibitors in Schnitzler's syndrome 83
Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study 82
Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak 80
Early development of new cardiovascular risk factors in the systemic vasculitides 76
Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et al 75
Clinical course and outcome of COVID-19 in patients with rheumatic diseases: Are all biological disease-modifying antirheumatic drugs alike? Response to: Â € Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al 72
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 70
Switching from intravenous to subcutaneous formulation of abatacept: Different results in a series of 21 patients 70
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: Ͽ Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and SLE, hydroxychloroquine and no SLE patients with COVID-19: A comment' by Joob and Wiwanitkit 68
Remission and Low-Disease Activity in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual 67
Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? 66
Pneumocephalus due to granulomatosis with polyangiitis 62
Development and implementation of the AIDA International Registry for patients with Behçet’s disease 61
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al 60
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 59
Striking abdominal aortic stenosis revealing Takayasu's arteritis 58
Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: Lessons from a case with severe pneumonia' by Guilpain et al 55
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 53
Response to: 'Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic' by Lecler et al 52
Pneumocephalus due to granulomatosis with polyangiitis 51
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors 50
Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 48
How I treat idiopathic patients with inflammatory myopathies in the clinical practice 47
Prevalence of COVID-19 among patients with rheumatic diseases: The need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al 47
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 46
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients 44
Non-steroidal anti-inflammatory treatment during covid-19: Friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et al 41
Humoral and T-cell immune response following three doses of SARS-CoV-2 mRNA vaccine in giant cell arteritis: analysis of a prospective cohort 39
Updates on the diagnosis and monitoring of giant cell arteritis 27
Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease 17
Totale 4.677
Categoria #
all - tutte 22.374
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.374


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 0 0 7
2021/2022203 4 1 13 2 4 14 1 11 9 6 27 111
2022/2023859 87 82 6 68 73 80 3 42 375 9 18 16
2023/2024396 63 75 18 16 30 83 25 32 3 20 15 16
2024/2025897 36 63 10 29 18 59 43 51 219 37 91 241
2025/20262.024 178 148 234 190 270 95 340 119 204 133 54 59
Totale 4.677